about
Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry.Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans.Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Prediction of plasma caffeine concentrations in young adolescents following ingestion of caffeinated energy drinks: a Monte Carlo simulation.Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.High-dose olanzapine for bipolar depression: proceed with caution.The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation.Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.The assessment of frailty in older people in acute care.Pharmacometrics: an underused resource in Australian clinical researchPharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metricsFrailty Should be Assessed Using Validated ScalesFurther Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 InhibitionPhase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
P50
Q33696224-C8C00DBD-2798-4FF0-AE9E-C533E3748318Q34297580-1A9C81A3-E0B6-4D8F-9034-29D0AB3FDCFDQ34320302-CFBFC60E-237A-4D4C-AFBF-A9C7B14DB109Q34554423-773537B5-3FB6-48A4-B42D-53C7334C20E4Q35537054-EF6A37EE-83AE-4DD6-B4F0-30E70F9DA5E4Q38103885-0DD3D6A4-68EF-4F4F-92F7-8F7B6E7F849EQ40795226-B996EA42-254B-47BC-B708-CE6869C2A073Q41907385-25193023-44DE-4BB9-9C62-38BCC173BD0DQ42283507-AB0A6B20-A398-49BF-BC6E-ED74F2A451DCQ46158661-8BA1D7D7-AD34-4010-B0BD-CBB94011E704Q47384439-1887589F-3583-43C7-A9F3-9FA867A57258Q48217479-E3FA884A-AA50-4861-A3FF-1F966490BA0AQ51859863-2D91B086-FCB5-44BF-ABB4-A70FE79203E3Q57415223-4E2AFAE7-007B-46C5-B59C-FE02EF0CE3B8Q61828173-D26C0A1E-17B5-4C86-851C-55973BE13AB5Q61828178-44260F53-2E87-4971-95EB-CEE214FD3ACCQ88732413-4868E30F-D12D-4F6A-9B06-F0CC6199B5D2Q90734561-740A097D-382F-4303-B3D9-DC332CC44DAD
P50
description
researcher ORCID ID = 0000-0002-9055-0123
@en
wetenschapper
@nl
name
Vidya Perera
@ast
Vidya Perera
@en
Vidya Perera
@es
Vidya Perera
@nl
type
label
Vidya Perera
@ast
Vidya Perera
@en
Vidya Perera
@es
Vidya Perera
@nl
prefLabel
Vidya Perera
@ast
Vidya Perera
@en
Vidya Perera
@es
Vidya Perera
@nl
P106
P1153
26041040000
P31
P496
0000-0002-9055-0123